Coverage
-
April 23, 2013
A New Jersey federal judge on Monday threw out an amended shareholder class action contending Pfizer Inc. deceived investors about the efficacy of Wyeth Inc.'s Alzheimer's drug bapineuzumab, finding the plaintiffs had not sufficiently alleged that Wyeth's statements about the drug were affirmatively false.
3 other articles on this case.
View all »